“A majority of the world is not familiar with...

“A majority of the world is not familiar with biosimilars and would probably be hesitant to use a biosimilar over a branded biologic. One could draw parallels to how generics were initially viewed when first introduced.”   —Oliver Steck, a principal in Deloitte & Touche LLP’s Risk & Financial Advisory practice, talked with Radar on Specialty Pharmacy about the state of the union on biosimilar uptake, and how the market will shake out as more self-administered biosimilars are expected to launch next year.

Subscribers may read the Radar on Specialty Pharmacy article in which this quote appeared online. Learn more about subscribing to AIS Health's publications.